Beta93% was sold under disclosed trading plans, 7% with no plan disclosed. The largest seller, Marc Stapley (Chief Executive Officer, Director), sold $8.9M. 45% of these sales were shares from exercising options.Share-of-stake figures for this company are being verified and will be added when that check is finished. Why
Price note. One filing reports a price of $47.73; it appears to be an error in the filing, so we've excluded it from totals. Filing
Price note. One filing reports a price of $49,015.00, about 991 times the same filer's other prices that week; it appears to be a decimal error for about $49.02, so we've excluded it from totals. Filing
Price note. One filing reports a price of $49.48; it appears to be an error in the filing, so we've excluded it from totals. Filing
A share of stake is shown for 0 of the 11 officers and directors who sold. 15 are left out Disclosed company stock is not an insider's whole wealth.i
Left out: Marc Stapley, Rebecca Chambers, Phillip Febbo, Annie McGuire, John Leite, Robert Epstein, Eliav Barr, Jonathan Wygant, Evan/ Jones, Muna Bhanji, Jens Holstein, David Shafer, Thomas Miller, Karin Eastham and Kevin Haas (share of stake is being verified).
Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| John Leite Global Chief Commercial Off | 4,015 | $40.00 | n/a | n/a | Sep 21, 2026 | Sep 22, 2026 |
"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.
Yes. Marc Stapley sold 191K shares ($8.9M) in the past 12 months, all of it under a trading plan disclosed in the filings.
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 93% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 7% had no disclosed plan. A trading plan schedules sales in advance.
No. Officers and directors reported no purchases in the past 12 months.
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| Marc Stapley Chief Executive Officer, Director | $8.9M 191K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Evan/ Jones Director | $2.0M 44K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Rebecca Chambers Chief Financial Officer | $1.9M 46K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Annie McGuire EVP, General Counsel | $1.7M 42K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Jonathan Wygant VP, Chief Accounting Officer | $1.5M 35K shares | Not confirmedshare of stake is being verified. Why | No plan disclosed |
| Karin Eastham Director | $1.5M 33K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| John Leite Global Chief Commercial Off | $1.2M 27K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Phillip Febbo Chief Scientific & Med Officer | $1.0M 27K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Jens Holstein Director | $628K 15K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Robert Epstein Director | $440K 10K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Muna Bhanji Director | $80K 1.9K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 16, 2025 | Sold | Held Oct 16, 2026 | Still held | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Marc Stapley!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Marc Stapley are complete. Chief Executive Officer, Director | n/a | −191K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Marc StapleyHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Marc Stapley are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −81Kwithheld by the company for taxes | ||||||||||||
Rebecca Chambers!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Rebecca Chambers are complete. Chief Financial Officer | n/a | −46K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Rebecca ChambersHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rebecca Chambers are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −30Kwithheld by the company for taxes | ||||||||||||
Phillip Febbo!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Phillip Febbo are complete. Chief Scientific & Med Officer | n/a | −27K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Phillip FebboHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Phillip Febbo are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −41Kwithheld by the company for taxes | ||||||||||||
Annie McGuire!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Annie McGuire are complete. EVP, General Counsel | n/a | −42K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Annie McGuireHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Annie McGuire are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −27Kwithheld by the company for taxes | ||||||||||||
John Leite!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for John Leite are complete. Global Chief Commercial Off | n/a | −27K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for John LeiteHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Leite are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −27Kwithheld by the company for taxes | ||||||||||||
Robert Epstein!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Robert Epstein are complete. Director | n/a | −10K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Robert EpsteinHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Epstein are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Eliav Barr!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Eliav Barr are complete. Director | n/a | 0 | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Eliav BarrHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eliav Barr are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Jonathan Wygant!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jonathan Wygant are complete. VP, Chief Accounting Officer | n/a | −35K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Jonathan WygantHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jonathan Wygant are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −7.1Kwithheld by the company for taxes | ||||||||||||
Evan/ Jones!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Evan/ Jones are complete. Director | n/a | −44K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Evan/ JonesHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Evan/ Jones are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Muna Bhanji!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Muna Bhanji are complete. Director | n/a | −1.9K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Muna BhanjiHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Muna Bhanji are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Jens Holstein!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jens Holstein are complete. Director | n/a | −15K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Jens HolsteinHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jens Holstein are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
David Shafer!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for David Shafer are complete. Director | n/a | 0 | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for David ShaferHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Shafer are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Thomas Miller!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Thomas Miller are complete. Director | n/a | 0 | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Thomas MillerHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Thomas Miller are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Karin Eastham!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Karin Eastham are complete. Director | n/a | −33K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Karin EasthamHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Karin Eastham are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($40.00 − strike price), using the most recent insider trade price on Form 4 (Sep 21, 2026), not a market close. | ||||||||||||
Kevin Haas!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kevin Haas are complete. Chief Dev and Tech Officer | n/a | 0 | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Kevin HaasHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kevin Haas are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Holdings and share of stake for Veracyte, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.
Officer and director open-market sales: $21.0M across 472,353 shares. Plan status and stated purpose are separate questions, and a sale can have both.
The lighter segment is sales with no plan disclosed in the filing ($1.5M), including tax-related sales outside a plan.
Sales with no 10b5-1 plan and no tax reference in the filing. $1.5M of it is Jonathan Wygant. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Jonathan Wygant, May 22, 2026
213,535 shares ($8.7M) were withheld by the company for taxes, which isn't a market sale.
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| Marc Stapley Chief Executive Officer, Director | 191K | $8.9M | 100% | 42% | Dec 4, 2025 to Jun 4, 2026 |
| Evan/ Jones Director | 44K | $2.0M | 100% | 10% | Nov 5, 2025 to Nov 25, 2025 |
| Rebecca Chambers Chief Financial Officer | 46K | $1.9M | 100% | 9% | Nov 5, 2025 to Sep 4, 2026 |
| Annie McGuire EVP, General Counsel | 42K | $1.7M | 100% | 8% | Nov 5, 2025 to Sep 4, 2026 |
| Jonathan Wygant VP, Chief Accounting Officer | 35K | $1.5M | 0% | 7% | Nov 7, 2025 to May 22, 2026 |
| Karin Eastham Director | 33K | $1.5M | 100% | 7% | Nov 5, 2025 to Jun 18, 2026 |
| John Leite Global Chief Commercial Off | 27K | $1.2M | 100% | 6% | Nov 25, 2025 to Sep 21, 2026 |
| Phillip Febbo Chief Scientific & Med Officer | 27K | $1.0M | 100% | 5% | Mar 2, 2026 to Sep 4, 2026 |
| Jens Holstein Director | 15K | $628K | 100% | 3% | Nov 20, 2025 to Sep 14, 2026 |
| Robert Epstein Director | 10K | $440K | 100% | 2% | May 20, 2026 to May 20, 2026 |
| Muna Bhanji Director | 1.9K | $80K | 100% | 0.4% | Sep 1, 2026 to Sep 1, 2026 |
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $0 | $0 | $0 | $0 |
| Nov 2025 | $3.9M | $3.5M | $0 | $450K |
| Dec 2025 | $2.5M | $2.5M | $0 | $0 |
| Jan 2026 | $0 | $0 | $0 | $0 |
| Feb 2026 | $0 | $0 | $0 | $0 |
| Mar 2026 | $3.2M | $3.2M | $0 | $0 |
| Apr 2026 | $0 | $0 | $0 | $0 |
| May 2026 | $1.9M | $838K | $0 | $1.1M |
| Jun 2026 | $8.2M | $8.2M | $0 | $0 |
| Jul 2026 | $0 | $0 | $0 | $0 |
| Aug 2026 | $0 | $0 | $0 | $0 |
| Sep 2026 | $1.3M | $1.3M | $0 | $0 |
| Oct 2026 | $0 | $0 | $0 | $0 |
More than usual: about 2x the 5-year average. 11 insiders sold; the average is 6 a year.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 16, 2026 Latest 12 months | 472K | 11 | $21.0M |
| Oct 16, 2025 1 year earlier | 229K | 9 | $8.3M |
| Oct 16, 2024 2 years earlier | 116K | 5 | $3.3M |
| Oct 17, 2023 3 years earlier | 368K | 6 | $9.8M |
| Oct 17, 2022 4 years earlier | 194K | 5 | $5.2M |
| Oct 17, 2021 5 years earlier | 270K | 5 | $13.3M |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Veracyte, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 622 Forms 3, 4 and 5 on record for Veracyte, Inc. (SEC CIK 1384101), filed from Oct 29, 2013 to Sep 22, 2026; 67 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.